|
|
DSpace at RU >
University Library >
Academic bibliography >
|
| Title: | The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. |
| Author(s): | Linden, I.J. van der Heijer, M. den (157196674) Afman, L.A. Gellekink, H. Vermeulen, S. (298981033) Kluijtmans, L.A.J. (168872579) Blom, H.J. (073808628) |
| Publication year: | 2006 |
| Document type: | Article / Letter to editor |
| Journal: | Journal of Molecular Medicine-JMM |
| ISSN: | 0946-2716 |
| Volume: | vol. 84 |
| Issue: | iss. 12 |
| Start page: | p. 1047 |
| End page: | p. 1054 |
| Abstract: | The methionine synthase reductase (MTRR) enzyme restores methionine synthase (MTR) enzyme activity and therefore plays an essential role in homocysteine remethylation. In some studies, the 66A>G polymorphism in the MTRR gene was associated with increased neural tube defect (NTD) risk. Using a case-control design, we studied the association between the MTRR 66A>G polymorphism and spina bifida risk in 121 mothers, 109 spina bifida patients, 292 control women, and 234 pediatric controls. Possible interactions between the MTRR 66A>G variant and the MTR 2756A>G polymorphism, the MTHFR 677C>T variant, plasma vitamin B12, and plasma methylmalonic acid (MMA) levels were examined in the 121 mothers and 292 control women. Meta-analyses were conducted to set the results of the case-control study in the context of eligible literature on the relation between the MTRR 66A>G variant and NTD risk. Finally, a transmission disequilibrium test was performed for 82 complete mother-father-child triads to test for preferential transmission of the MTRR risk allele. In our case-control study, the MTRR 66A>G polymorphism had no influence on spina bifida risk in children [odds ratio (OR) 0.6, 95% confidence interval (CI) 0.4-1.1]. The MTRR 66GG genotype increased maternal spina bifida risk by 2.1-fold (OR 2.1, 95% CI 1.3-3.3). This risk became more pronounced in combination with the MTHFR 677TT genotype (OR 4.0, 95% CI 1.3-12.5). Moreover, we demonstrate a possible interaction between the MTRR 66GG genotype and high plasma MMA levels (OR 5.5, 95% CI 2.2-13.5). The meta-analyses demonstrated that the maternal MTRR 66GG genotype was associated with an overall 55% (95% CI 1.04-2.30) increase in NTD risk and that the MTRR 66GG genotype did not increase NTD risk in children (OR 0.96, 95% CI 0.46-2.01). These data show that the MTRR 66GG genotype is a maternal risk factor for spina bifida especially when intracellular vitamin B12 status is low. |
| Subject: | EBP 1: Determinants in Health and Disease UMCN 1.5: Interventional oncology UMCN 2.2: Vascular medicine and diabetes UMCN 5.2: Endocrinology and reproduction |
| Organization: | UMCN Extern Epidemiology, Biostatistics & HTA Paediatrics Endocrinology |
| Appears in Collections: | Academic bibliography
|
|
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2066/51023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
|